FDG–PET. A possible prognostic factor in head and neck cancer

Ahuja V, Coleman RE, Herndon J, Patz Jr EF (1998) The prognostic significance of fluorodeoxyglucose positron emission tomography imaging for patients with nonsmall cell lung carcinoma. Cancer 83: 918–924

Braams JW, Pruim J, Freling NJM, Nikkels PG, Roodenburg JL, Boering G, Vaalburg W, Vermey A (1995) Detection of lymph node metastases of squamous cell cancer of the head and neck with FDG-PET and MRI. J Nucl Med 36: 211–216

Conti PS, Strauss LG (1991) The applications of PET in clinical oncology. J Nucl Med 32: 623–648

Haberkorn U, Strauss L, Reisser CH, Haag D, Dimitrikopoulou A, Ziegler S, Oberdorfer F, Rudat V, van Kaick G (1991) Glucose uptake, perfusion and cell proliferation in head and neck tumours: relation of positron emission tomography to flow cytometry. J Nucl Med 32: 1548–1555

Hain SF, O'Doherty MJ, Timothy AR, Leslie MD, Harper PG, Huddart RA (2000) Fluorodeoxyglucose positron emission tomography in the evaluation of germ cell tumours at relapse. Br J Cancer 83: 863–869

Hallett WA, Marsden PK, Cronin BF, O'Doherty MJ (2001) Effect of corrections for blood glucose and body size on [18F] FDG PET standardised uptake values in lung cancer. Eur J Nucl Med 28: 919–922

Hermanek P, Sobin LH (1992) UICC TNM classification of malignant tumours 4th edn Berlin: Springer-Verlag

Kitagawa Y, Sadato N, Azuma H, Ogasawara T, Yoshida M, Ishii Y, Yonekura Y (1999) FDG PET to evaluate combined intra-arterial chemotherapy and radiotherapy of head and neck neoplasms. J Nucl Med 40: 1132–1137

Lodge MA, Lucas JD, Marsden PK, Cronin BF, O'Doherty MJ, Smith MA (1999) A PET study of 18FDG uptake in soft tissue masses. Euro J Nuc Med 26: 22–30

Minn H, Joensuu H, Ahonen A, Klemi P (1988) Fluorodeoxyglucose imaging: a method to assess the proliferative activity of human cancer in vivo. Cancer 61: 1776–1781

Minn H, Zasadny KR, Quint LE (1995) Lung cancer: reproducibility of quantitative measurements for evaluating 2-[F-18]-fluoro-2-deoxy-D-glucose uptake at PET. Radiology 196: 167–173

Minn H, Lapela M, Klemi PJ, Grenman R, Leskinen S, Liindholm P, Bergman J, Eronen E, Haaparanta M, Joensuu H (1997) Prediction of survival with fluorine-18-fluorodeoxyglucose and PET in head and neck cancer. J Nucl Med 38: 1907–1911

Nowak B, Di Martino E, Janicke S, Cremerius U, Adam G, Zimny M, Reinartz P, Bull U (1999) Diagnostic evaluation of malignant head and neck cancer by F-18-FDG PET compared to CT/MRI. Nuklearmedizin 38: 312–318

Okada J, Yoshikawa K, Itami M, Imaseki K, Uho K, Itami J, Kuyoma J, Mikata A, Arimozu N (1992) Positron emission tomography using fluorine-18-fluorodeoxyglucose in malignant lymphoma: a comparison with proliferative activity. J Nucl Med 33: 325–329

Patronas NJ, Di Chiro G, Kufta C, Bairamian D, Kornblith PL, Simon R, Larson SM (1985) Prediction of survival in glioma patients by means of positron emission tomography. J Neurosurg 62: 816–822

Rege S, Maas A, Chaiken L, Hoh CK, Choi Y, Lufkin R, Anzai Y, Julliard G, Maddahi J, Phelps ME (1994) Use of positron emission tomography with flurodeoxyglucose in patients with extracranial head and neck cancers. Cancer 73: 3047–3058

Saunders CA, Dussek JE, O'Doherty MJ, Maisey MN (1999) Evaluation of fluorine-18-Fluorodeoxyglucose whole Body Positron emission Tomography Imaging in the Staging of Lung cancer. Ann Thorac Surg 67: 7790–7797

Tayek JA (1992) A review of cancer cachexia and abnormal glucose metabolism in humans with cancer. J Am Coll Nutr 11: 445–456

Vansteenkiste JF, Stroobants SG, Dupont PJ, De Leyn PR, Verbeken EK, Deneffer GJ, Mortlemans LA, Demedts MG (1999) Prognostic importance of the standardized uptake value on 18F-Fluoro-2-deoxy-glucose positron emission tomography scan in non-small-cell lung cancer: an analysis of 125 cases. J Clin Oncol 17: 3201–3206

Warburg O (1956) On the origin of cancer cells. Science 123: 309–314